In a retrospective study of 393 patients, 51.9% had at least 1 abnormal LFT during follow-up, but only 1.1% had elevations above 3 times the upper limit of normal.
News|Articles|July 10, 2026
5 Dermatology Approvals to Know from the First Half of 2026
Author(s)Patrick Campbell
Recapping 5 practice-changing FDA decisions from the first half of 2026, including icotrokinra, expanded pediatric indications, and more!
Advertisement
Advertisement
The first half of 2026 has unfolded during a period of steady momentum in dermatology.
Related to this article
Patients with plaque psoriasis treated with roflumilast cream or foam reported greater improvements in sexual function and relationships vs vehicle, including those with genital involvement at baseline.
By week 36, combination therapy altered 482 proteins and 467 genes vs 140 and 16 with ixekizumab alone in exploratory TOGETHER-PsO data.
The approval of the oral BTKi rests on a phase 3 result of 29.3% complete response from hives vs 14.0% with placebo at week 12.
Celltrion’s US launch of omalizumab-igec adds an interchangeable biosimilar option for eligible patients with chronic spontaneous urticaria.
At 2 years, 70% of patients on oral icotrokinra for scalp, genital, or hand/foot psoriasis had clear or almost clear skin, with no new safety signals.
Phase 3 LATITUDE Atlas data presented at EADV 2026 showed higher rates of complete and near-complete skin clearance with zasocitinib compared with deucravacitinib.
Treatment success reached 56.7% and total lesions fell 71.8% with up to 52 weeks of oral denifanstat, with no adverse event-related discontinuations.
Advertisement
Advertisement